Puma Biotechnology reported $80.54M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Daiichi Sankyo JPY 592.49B 17.75B Sep/2026
Exelixis USD 658.69M 30M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Glaxosmithkline GBP 8.89B 1.2B Sep/2026
Incyte USD 1.56B 110M Sep/2026
MacroGenics USD 32.83M 12.03M Jun/2026
Moderna USD 1.31M 98.69M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Takeda JPY 1.19T 32.9B Sep/2026
TG Therapeutics USD 259.94M 19.6M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026